These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30398720)

  • 1. Top 40 Medicare Part D prescription drugs Ranked by total payments in 2014.
    Mod Healthc; 2016 Oct; 46(36):42. PubMed ID: 30398720
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicare Part D update--lessons learned and unfinished business.
    Neuman P; Cubanski J
    N Engl J Med; 2009 Jul; 361(4):406-14. PubMed ID: 19625722
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-related nonadherence in the Medicare program: the impact of Part D.
    Kennedy JJ; Maciejewski M; Liu D; Blodgett E
    Med Care; 2011 May; 49(5):522-6. PubMed ID: 21430574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.
    Gellad WF; Ennis M; Kuza CC
    N Engl J Med; 2019 May; 380(18):1688-1690. PubMed ID: 30946552
    [No Abstract]   [Full Text] [Related]  

  • 7. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 8. The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products.
    Kwa MC; Tegtmeyer K; Welty LJ; Raney SG; Luke MC; Xu S; Kong B
    Arch Dermatol Res; 2020 Oct; 312(8):559-565. PubMed ID: 32055932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
    Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
    Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
    Hwang TJ; Dusetzina SB; Feng J; Maini L; Kesselheim AS
    JAMA; 2019 Jul; 322(3):267-269. PubMed ID: 31310287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
    Duggan M; Morton FS
    Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
    [No Abstract]   [Full Text] [Related]  

  • 12. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations for Lowering Prescription Drug Spending in Public Programs.
    Jazowski SA; Dusetzina SB
    Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
    [No Abstract]   [Full Text] [Related]  

  • 14. Relief in Sight - Estimated Savings under Medicare Part D Redesign.
    Dusetzina SB
    N Engl J Med; 2021 Dec; 385(26):e93. PubMed ID: 34758246
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB; Pizer SD
    Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty pharmacy management will become more intense.
    Collins S
    Manag Care; 2010 Oct; 19(10):20-3. PubMed ID: 21049783
    [No Abstract]   [Full Text] [Related]  

  • 17. Association Between Prescription Drug Insurance and Health Care Utilization Among Medicare Beneficiaries.
    Alexander GC; Schiman C; Kaestner R
    Med Care Res Rev; 2018 Apr; 75(2):153-174. PubMed ID: 29148319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
    Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
    Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.
    Socal MP; Wang Y; Plummer E; Anderson GF; Bai G
    JAMA; 2024 Jan; 331(1):72-75. PubMed ID: 38095888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.